Azopharma Product Development Group, is pleased to announce the completed expansion of its cGMP cytotoxic and highly-potent compound facilities at its South Florida-Hollywood location.

The expansion adds an additional 7,000ft² of space to Azopharma’s current capacity and includes three manufacturing suites with dedicated equipment, analytical instrumentation and staff. The expansion further strengthens Azopharma’s position as an industry leader in manufacturing and processing of cytotoxic and highly potent compounds for pharmaceutical development.

The cytotoxic suites join 11 new cGMP suites, two aseptic cGMP suites, and two explosion proof suites completed earlier this year and brings Azopharma’s manufacturing suite total to 29. Phil Meeks, CEO of Azopharma comments, “We are excited to see our new cytotoxic suites up and running. These suites are key to maintaining our position as a leader in total product development. Our capabilities are unique within the industry based on the depth and scope of our development capabilities which range from discovery to commercialization.” The manufacturing suite expansion is complimented by the addition of state-of-the-art equipment including the MG Futura Capsule Filler, Bausch & Strobel Aseptic Filling Isolator and XcelodoseTM powder microdosing system.

Azopharma Product Development Group Includes:

• Azopharma Contract Pharmaceutical Services™ - Integrated product development including synthesis, analysis, formulation and CTM manufacturing for all dosage forms
• AniClin Preclinical Services™ - Preclinical services in support of early product development
• AvivoClin Clinical Services™ - Human clinical pharmacology and monitoring services for Phase I-III clinical trials